# Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies

> **NCT04418661** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 65 (actual)

## Conditions studied

- Metastatic Neoplasm

## Interventions

- **DRUG:** Vociprotafib
- **DRUG:** Pembrolizumab
- **DRUG:** Adagrasib

## Key facts

- **NCT ID:** NCT04418661
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-09
- **Primary completion:** 2024-04-04
- **Final completion:** 2024-04-04
- **Target enrollment:** 65 (ACTUAL)
- **Why stopped:** Sponsor's decision not related to any safety concern
- **Last updated:** 2025-05-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04418661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04418661, "Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04418661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*